Loading clinical trials...
Loading clinical trials...
Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ALVR105 Posoleucel (ALVR105,Viralym-M) Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV Infection and/or Disease, in High-Risk Patients After Allogeneic Hematopoietic Cell Transplant
Conditions
Interventions
Posoleucel (ALVR105)
Placebo
Locations
88
United States
University of Alabama at Birmingham Children's of Alabama
Birmingham, Alabama, United States
Honor Health Research Institute
Scottsdale, Arizona, United States
City of Hope
Duarte, California, United States
University of California, Los Angeles (UCLA)
Los Angeles, California, United States
Stanford University
Palo Alto, California, United States
University of California San Francisco - Benioff Children's Hospital
San Francisco, California, United States
Start Date
March 24, 2022
Primary Completion Date
January 30, 2024
Completion Date
January 30, 2024
Last Updated
May 16, 2024
NCT04542733
NCT07294547
NCT06926894
NCT05626530
NCT02007356
NCT05701228
Lead Sponsor
AlloVir
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions